Trial Profile
REduCing Immunogenicity to PegloticasE (RECIPE) Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Pegloticase (Primary)
- Indications Gout
- Focus Proof of concept; Therapeutic Use
- Acronyms RECIPE
- 13 Oct 2021 Status changed from active, no longer recruiting to completed.
- 07 Apr 2021 Results published in the Horizon Therapeutics plc Media Release.
- 22 Mar 2021 Results assessing efficacy of reducing immunogenicity of pegloticase (RECIPE) with concomitant medications of mycophenolate mofetil in refractory gout patients, published in the Arthritis and Rheumatology.